At a glance
ClinicalIndex Comparison RecordN/ACompleted· 25 enrolled
Drug / intervention
dolutegravir +1 moredrug
Likely dose
dolutegravir 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/Hepatitis C Virus (HCV) Seronegative Volunteers
In Brief
A clinical study evaluating dolutegravir and simeprevir for HIV and Hepatitis C. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The investigator believes simeprevir concentrations are unchanged when administered in combination with dolutegravir relative to administration alone. The investigator believes dolutegravir concentrations are unchanged when administered in combination with simeprevir. Additionally, the investigator believes simeprevir and dolutegravir are safe when administered alone and in combination.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV, Hepatitis C
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartFeb 2016
Primary CompletionOct 2016
TodayJul 2026
First PostedApr 1, 2015
Enrollment StartFeb 1, 2016
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 11.3 years ago
Interventions
dolutegravirdrug
dolutegravir tablets 50mg, once daily x 7 days.
simeprevirdrug
simeprevir tablets 150mg, once daily x 7 days.